Which systemic autoimmune disorders can present with a persistent cough and chronic pericarditis, and what initial diagnostic work‑up and treatment should be undertaken?

Autoimmune Disease with Cough and Chronic Pericarditis

The most likely systemic autoimmune disorders presenting with both persistent cough and chronic pericarditis are systemic lupus erythematosus (SLE), Sjögren's syndrome, rheumatoid arthritis, and scleroderma—with SLE being the most common culprit. 1

Key Autoimmune Diseases to Consider

The 2015 ESC Guidelines explicitly identify that pericardial involvement is common in:

• Systemic lupus erythematosus (most frequent cardiac manifestation is pericarditis)
• Sjögren's syndrome
• Rheumatoid arthritis
• Scleroderma
• Systemic vasculitides
• Behçet's syndrome
• Sarcoidosis
• Inflammatory bowel diseases 1

Critical clinical insight: Approximately 5-15% of patients with acute or recurrent pericarditis have an underlying systemic autoimmune disease, though pericardial involvement rarely occurs as the first manifestation 1. However, in a specialized cohort study, when patients under age 50 presented with pericardial effusion and extra-cardiac symptoms, the probability of underlying autoimmune disease reached 89.7% 2.

Diagnostic Work-Up Algorithm

Initial Assessment

1. Age and sex matter: Younger patients (<50 years) and female sex significantly increase likelihood of autoimmune etiology 2

2. Screen for extra-cardiac symptoms (these are the red flags):

   • Arthralgia or frank arthritis
   • Myalgia
   • Raynaud phenomenon
   • Skin rash (malar rash, photosensitivity, discoid lesions)
   • Sicca symptoms (dry eyes/mouth)
   • Oral/genital ulcers
   • Constitutional symptoms (fever, weight loss, fatigue) 2

3. Mandatory laboratory panel:

   • CRP (essential for monitoring disease activity and treatment response) 1
   • Complete blood count (cytopenias in SLE)
   • Comprehensive metabolic panel (renal involvement)
   • ANA with reflex to specific antibodies (anti-dsDNA, anti-Smith, anti-Ro/La, anti-Scl-70, RF, anti-CCP)
   • Complement levels (C3, C4—low in active SLE)
   • Urinalysis (proteinuria, cellular casts)

4. Imaging:

   • Echocardiogram (assess effusion size, tamponade physiology, myocardial involvement) 1
   • Chest CT or cardiac MRI for atypical cases showing pericardial inflammation, edema, and contrast enhancement 1
   • Chest X-ray (pulmonary involvement causing cough—interstitial lung disease in scleroderma/RA, pleuritis in SLE)

Rule Out Infectious Causes First

Before attributing pericarditis to autoimmune disease, exclude tuberculosis (especially in endemic areas) and bacterial causes, as these carry 20-30% risk of constrictive pericarditis versus 2-5% for autoimmune etiologies 1.

Specialist Consultation

Rheumatology consultation is warranted when clinical features suggest systemic autoimmune disease 1. The underlying disease typically has already been diagnosed by classical symptoms, but pericarditis can be the presenting manifestation in 12/23 cases (52%) in one series 2.

Treatment Approach

For Chronic Pericarditis (>3 months duration) 1

First-line therapy remains NSAIDs plus colchicine, even in autoimmune cases:

• Aspirin 750-1000 mg every 8 hours OR Ibuprofen 600 mg every 8 hours
• Plus Colchicine 0.5 mg once daily (<70 kg) or 0.5 mg twice daily (≥70 kg) for 3 months
• Gastroprotection mandatory 1
• Monitor CRP to guide treatment duration 1

When Autoimmune Disease is Confirmed

Low-dose corticosteroids should be considered when there is a specific indication such as autoimmune disease (Class IIa recommendation) 1:

• Prednisone 0.2-0.5 mg/kg/day (NOT high-dose 1.0 mg/kg/day)
• Maintain initial dose until symptom resolution and CRP normalization
• Then taper gradually 1

Critical pitfall: Corticosteroids are NOT first-line therapy for pericarditis (Class III recommendation) because they favor chronic evolution and promote drug dependence 1. Use them only after NSAIDs/colchicine failure or when specifically indicated for the underlying autoimmune disease.

Treatment Targeted at Underlying Disease

The treatment is especially targeted at control of the systemic underlying disease 1. This means:

• For SLE: hydroxychloroquine, immunosuppressants (azathioprine, mycophenolate), biologics if needed
• For RA/scleroderma: DMARDs, biologics
• IL-1 inhibitors (anakinra, rilonacept) are emerging as steroid-sparing agents for refractory autoimmune pericarditis 3, 4

Exercise Restriction

• Non-athletes: Restrict exercise until symptom resolution and normalization of CRP, ECG, and echocardiogram
• Athletes: Minimum 3 months restriction 1

Addressing the Cough Component

The persistent cough in this context likely represents:

1. Pleuropulmonary involvement of the autoimmune disease (pleuritis, interstitial lung disease)
2. Pleural effusion (common in post-cardiac injury syndromes and autoimmune pericarditis) 1
3. Pulmonary infiltrates associated with systemic disease

The cough should improve as the underlying autoimmune disease is controlled. If isolated to respiratory symptoms, consider high-resolution chest CT to evaluate for interstitial lung disease, particularly in scleroderma or rheumatoid arthritis.

Prognosis Considerations

Autoimmune/immune-mediated etiologies carry an intermediate risk (2-5%) of developing constrictive pericarditis, compared to <1% for idiopathic cases 1. This underscores the importance of aggressive treatment of the underlying autoimmune condition and avoiding inadequate initial therapy, which is a common cause of recurrence 1.

Corticosteroid dependence occurs in 28.7% of patients with recurrent pericarditis and is associated with chronic pain 5, making the steroid-sparing approach with colchicine and treatment of the underlying autoimmune disease even more critical.